Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Viagra’s End Begins: Generic Sildenafil Launches For Revatio

This article was originally published in The Pink Sheet Daily

Executive Summary

Apotex has launched sildenafil for treatment of pulmonary arterial hypertension; its product is bioequivalent to Revatio, Pfizer’s sildenafil formulation for PAH, not Viagra; FDA also approved Watson, Dr. Reddy’s and Torrent sildenafil ANDAs.

You may also be interested in...

Teva’s Generic Viagra Launch Will Be Offset By Generic Cialis

Patent settlement will enable Teva to enter the market more than three years before Viagra’s use patent expires; Pfizer suddenly parts ways with General Counsel Amy Schulman.

Actelion And Bayer Hope Novel Drugs Can Take Over The Pulmonary Hypertension Market

Impressive Phase III trial data on Actelion’s macitentan and Bayer’s riociguat generated big noises at the annual meeting of the American College of Chest Physicians in Atlanta and should support regulatory filings for the two therapies.

Viagra Patent Ruling Could Deter Appeal, Support Pfizer Position In Pending Cases

Teva Pharmaceuticals USA Inc. is considering whether to appeal a federal court decision upholding the validity of Pfizer Inc.'s Viagra (sildenafil) patent.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts